MorphoSys AG
Biopharmaceutical company developing antibody-based medicines for cancer patients.
MOR | F
Overview
Corporate Details
- ISIN(s):
- DE000A3H2XW6 (+1 more)
- LEI:
- 529900493806K77LRE72
- Country:
- Germany
- Address:
- Semmelweisstr. 7, 82152 Planegg
- Website:
- https://www.morphosys.com/
- Sector:
- Manufacturing
Description
MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-27 16:00 |
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual G…
|
English | 11.5 KB | ||
| 2024-08-05 07:30 |
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and N…
|
English | 12.1 KB | ||
| 2024-07-19 16:46 |
MorphoSys AG: Korrektur: Bekanntmachung der Einberufung zur Hauptversammlung am…
|
German | 259.7 KB | ||
| 2024-07-19 15:07 |
MorphoSys AG: Bekanntmachung der Einberufung zur Hauptversammlung am 27.08.2024…
|
German | 259.7 KB | ||
| 2024-07-18 16:00 | English | 4.6 KB | |||
| 2024-07-12 22:02 |
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
|
English | 13.2 KB | ||
| 2024-07-12 14:34 |
Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00
|
English | 12.6 KB | ||
| 2024-07-05 16:00 | English | 3.9 KB | |||
| 2024-07-02 16:00 | English | 14.6 KB | |||
| 2024-06-21 16:00 | English | 14.3 KB | |||
| 2024-06-20 08:25 |
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merge…
|
English | 21.4 KB | ||
| 2024-06-20 08:06 |
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of …
|
English | 12.3 KB | ||
| 2024-06-10 16:01 | English | 13.4 KB | |||
| 2024-06-10 16:00 | English | 13.4 KB | |||
| 2024-06-06 22:19 |
Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of Morp…
|
English | 10.9 KB |
Automate Your Workflow. Get a real-time feed of all MorphoSys AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MorphoSys AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MorphoSys AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-20 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 775.25 EUR |
| 2023-06-07 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 52,800.00 EUR |
| 2023-06-06 | Cluzel, Dr. Marc | Supervisory board | Buy | None | 24,280.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 13,800.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 7,479.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 4,186.00 EUR |
| 2022-11-30 | Reissner, Thomas | Supervisory board | Buy | None | 2,698.00 EUR |
| 2022-11-29 | Reissner, Thomas | Supervisory board | Buy | None | 8,100.00 EUR |
| 2022-11-29 | Reissner, Thomas | Supervisory board | Buy | None | 5,000.00 EUR |
| 2022-11-28 | Vermeylen, Krisja | Supervisory board | Buy | None | 14,860.00 EUR |
Peer Companies
